Cuong Do is the founder of M6P Therapeutics. He previously founded Callidus Biopharma and Lysodel Therapeutics. Callidus developed a drug for Pompe disease that was acquired by Amicus Therapeutics for further development. Do is President of Samsung’s Global Strategy Group and was formerly the Chief Strategy Officer for Merck and a board member of WuXi AppTec, the largest contract research organization serving the pharmaceutical industry.
Stuart Kornfeld, co-founder of M6P Therapeutics, is a professor in the Department of Medicine and the Department of Biochemistry and Molecular Biophysics at Washington University Medical School. Dr. Kornfeld has devoted decades to understanding mannose 6-phosphate and is considered the leading expert on this substance. He has advised multiple companies working on lysosomal storage disorders.
Lin Liu, Director of R&D at M6P Therapeutics, is co-inventor of a modified version of the GlcNAc-1-phosphotransferase enzyme and co-author of the patent application for it. Dr. Liu was previously a post-doctoral fellow in Dr. Kornfeld’s lab.